India · Delayed Price · Currency is INR Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 220.36 billion. The enterprise value is 261.43 billion.
| Market Cap | 220.36B |
| Enterprise Value | 261.43B |
Important Dates
The last earnings date was Wednesday, January 28, 2026.
| Earnings Date | Jan 28, 2026 |
| Ex-Dividend Date | Jul 16, 2025 |
Share Statistics
| Current Share Class | 1.33B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.55% |
| Shares Change (QoQ) | -0.05% |
| Owned by Insiders (%) | 0.19% |
| Owned by Institutions (%) | 23.26% |
| Float | 600.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 99.96 |
| PS Ratio | 2.48 |
| PB Ratio | 2.73 |
| P/TBV Ratio | 5.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -159.79 |
| EV / Sales | 2.95 |
| EV / EBITDA | 24.78 |
| EV / EBIT | 113.36 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 4.87 |
| Debt / FCF | n/a |
| Interest Coverage | 0.48 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -4.27% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 16.20M |
| Profits Per Employee | -298,776 |
| Employee Count | 5,476 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Piramal Pharma has paid 2.17 billion in taxes.
| Income Tax | 2.17B |
| Effective Tax Rate | 404.45% |
Stock Price Statistics
The stock price has decreased by -17.13% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -17.13% |
| 50-Day Moving Average | 167.25 |
| 200-Day Moving Average | 191.28 |
| Relative Strength Index (RSI) | 54.87 |
| Average Volume (20 Days) | 193,970 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 88.71 billion and -1.64 billion in losses. Loss per share was -1.24.
| Revenue | 88.71B |
| Gross Profit | 54.10B |
| Operating Income | 1.71B |
| Pretax Income | 537.40M |
| Net Income | -1.64B |
| EBITDA | 9.54B |
| EBIT | 1.71B |
| Loss Per Share | -1.24 |
Balance Sheet
The company has 7.44 billion in cash and 48.51 billion in debt, with a net cash position of -41.07 billion.
| Cash & Cash Equivalents | 7.44B |
| Total Debt | 48.51B |
| Net Cash | -41.07B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 80.74B |
| Book Value Per Share | 61.03 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 60.98%, with operating and profit margins of 1.92% and -1.84%.
| Gross Margin | 60.98% |
| Operating Margin | 1.92% |
| Pretax Margin | 0.61% |
| Profit Margin | -1.84% |
| EBITDA Margin | 10.76% |
| EBIT Margin | 1.92% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 0.09%.
| Dividend Per Share | 0.14 |
| Dividend Yield | 0.09% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 0.55% |
| Shareholder Yield | 0.64% |
| Earnings Yield | -0.74% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |